Safety and Efficacy of Inhaled Interferon-β1a (SNG001) in a Phase II Randomized Controlled Trial of Adults with Mild-to-Moderate COVID-19

Conference Reports for NATAP

Conference on Retroviruses
and Opportunistic Infections
Seattle, Washington
Feb 19-22 2023


Safety and Efficacy of Inhaled Interferon-β1a (SNG001) in a Phase II Randomized Controlled Trial of Adults with Mild-to-Moderate COVID-19

	CROI 2023 Feb 20-23 William A. Fischer II, MD On Behalf of the ACTIV-2/A5401 Team Associate Professor of Medicine Director of Emerging Pathogens Division of Pulmonary and Critical Care Medicine The University of North Carolina at Chapel Hill